Senate deadlock continues as Democrats refuse to end the government shutdown without concessions on healthcare and other priorities.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Senate deadlock continues as Democrats refuse to end the government shutdown without concessions on healthcare and other priorities.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.